Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study-Reference-Cited by-同舟云学术

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

Published:2006-07-13 Issue:9 Volume:20 Page:1526-1532
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Delannoy A, ,Delabesse E,Lhéritier V,Castaigne S,Rigal-Huguet F,Raffoux E,Garban F,Legrand O,Bologna S,Dubruille V,Turlure P,Reman O,Delain M,Isnard F,Coso D,Raby P,Buzyn A,Caillères S,Darre S,Fohrer C,Sonet A,Bilhou-Nabera C,Béné M-C,Dombret H,Berthaud P,Thomas X

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404320.pdf

Reference14 articles.

1. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357–2366.

2. Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogenetique Hematologique. Blood 1996; 87: 3135–3142.

3. Houot R, Tavernier E, Le QH, Lheritier V, Thiebaut A, Thomas X . Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology 2004; 9: 369–976.

4. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145.

5. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971.

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL;Journal of Clinical Oncology;2023-12-21

2. Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison;Advances in Therapy;2023-05-19

3. Moving Toward a Chemotherapy-Free Approach for Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia;Advances in Oncology;2023-05

4. Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis;Clinical Lymphoma Myeloma and Leukemia;2023-03

5. Philadelphia chromosome-positive acute lymphoblastic leukemia carrying the p230 μ-<i>BCR-ABL1</i> fusion gene;Tenri Medical Bulletin;2022-12-25